Display options
Cite
Chao BH, Lepeak L, Leal T, et al. Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis. 2011;2011:530183doi: 10.1155/2011/530183.
Chao, B. H., Lepeak, L., Leal, T., & Robins, H. I. (2011). Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis, 2011530183. https://doi.org/10.1155/2011/530183
Chao, Bo H, et al. "Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes." Thrombosis vol. 2011 (2011): 530183. doi: https://doi.org/10.1155/2011/530183
Chao BH, Lepeak L, Leal T, Robins HI. Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12. PMID: 22084664; PMCID: PMC3195390.
Copy Download .nbib Format: NLM
Share it on

Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12.

Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Thrombosis

Bo H Chao, Lisa Lepeak, Ticiana Leal, H Ian Robins

Affiliations

  1. Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison WI 53792, USA.

PMID: 22084664 PMCID: PMC3195390 DOI: 10.1155/2011/530183

Abstract

Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of venous thromboembolic events (VTE) is readily accomplished. The introduction of low-molecular-weight heparin (LMWH) approximately two decades ago (in contrast to unfractionated heparin and vitamin K antagonists) has provided a class of agents with a favorable therapeutic index. In the review to follow, the literature regarding the use of LMWH in oncologic patient populations is summarized. Topics addressed include prophylaxis, and treatment as well as consideration of the potential anti-neoplastic properties of this class of drugs.

References

  1. J Neurol. 1975 Jul 2;209(3):217-24 - PubMed
  2. Clin Exp Metastasis. 1990 Mar-Apr;8(2):165-71 - PubMed
  3. Lancet. 1992 Feb 22;339(8791):441-5 - PubMed
  4. J Clin Oncol. 2003 Nov 15;21(22):4194-9 - PubMed
  5. Cancer Metastasis Rev. 1983;2(1):41-73 - PubMed
  6. N Engl J Med. 2001 Jun 21;344(25):1951-2 - PubMed
  7. Pharmacotherapy. 2001 Feb;21(2):218-34 - PubMed
  8. J Clin Oncol. 1996 Sep;14(9):2560-8 - PubMed
  9. Lancet Oncol. 2009 Oct;10(10):943-9 - PubMed
  10. J Neurosurg. 1990 Sep;73(3):429-35 - PubMed
  11. Cancer. 1984 May 15;53(10):2046-52 - PubMed
  12. Semin Thromb Hemost. 1988 Jan;14(1):18-27 - PubMed
  13. J Clin Oncol. 2009 Oct 10;27(29):4848-57 - PubMed
  14. Ann Oncol. 2007 Oct;18(10):1660-5 - PubMed
  15. Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 - PubMed
  16. Chest. 2008 Jun;133(6 Suppl):141S-159S - PubMed
  17. N Engl J Med. 1998 Jul 9;339(2):80-5 - PubMed
  18. Eur J Cancer. 1997 Sep;33(10):1592-6 - PubMed
  19. J Thromb Haemost. 2007 Mar;5(3):632-4 - PubMed
  20. Clin Cancer Res. 2004 Nov 1;10(21):7238-43 - PubMed
  21. Semin Thromb Hemost. 1988 Jan;14(1):88-94 - PubMed
  22. Thromb Haemost. 1991 Mar 4;65(3):251-6 - PubMed
  23. J Cell Biol. 1986 May;102(5):1979-84 - PubMed
  24. Neurosurgery. 1994 Mar;34(3):389-94; discussion 394-5 - PubMed
  25. Arch Intern Med. 1995 Mar 27;155(6):601-7 - PubMed
  26. N Engl J Med. 2000 Dec 21;343(25):1846-50 - PubMed
  27. Arch Intern Med. 1993 Jul 12;153(13):1541-6 - PubMed
  28. J Clin Oncol. 2009 Oct 10;27(29):4839-47 - PubMed
  29. J Thromb Haemost. 2006 Mar;4(3):529-35 - PubMed
  30. BMJ. 2006 Feb 11;332(7537):325-9 - PubMed
  31. J Natl Cancer Inst. 1999 Jan 6;91(1):22-36 - PubMed
  32. Biomed Pharmacother. 2004 May;58(4):213-9 - PubMed
  33. Am J Cardiol. 1998 Sep 10;82(5B):33L-36L - PubMed
  34. N Engl J Med. 2002 Mar 28;346(13):975-80 - PubMed
  35. Arch Intern Med. 2004 May 10;164(9):963-8 - PubMed
  36. Cancer Chemother Pharmacol. 1997;39(5):462-6 - PubMed
  37. Science. 1983 Aug 19;221(4612):719-25 - PubMed
  38. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001100 - PubMed
  39. N Engl J Med. 1999 Sep 9;341(11):793-800 - PubMed
  40. Medicine (Baltimore). 1999 Sep;78(5):285-91 - PubMed
  41. Bull N Y Acad Med. 1952 Jul;28(7):462-8 - PubMed
  42. Arch Intern Med. 2000 Mar 27;160(6):809-15 - PubMed
  43. Cancer. 2007 Nov 15;110(10):2339-46 - PubMed
  44. Pharmacol Rev. 2001 Mar;53(1):93-105 - PubMed
  45. J Med. 1975;6(1):61-4 - PubMed
  46. Neurosurgery. 1994 Feb;34(2):280-96; discussion 296 - PubMed
  47. Cancer. 1979 Aug;44(2):732-41 - PubMed
  48. J Vasc Surg. 1996 Nov;24(5):774-82 - PubMed
  49. Arch Intern Med. 2006 Feb 27;166(4):458-64 - PubMed
  50. Haemostasis. 1997;27 Suppl 1:25-31 - PubMed
  51. Thromb Haemost. 2003 Sep;90(3):446-55 - PubMed
  52. Mayo Clin Proc. 2006 Jun;81(6):758-67 - PubMed
  53. Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1113-7 - PubMed
  54. Isr J Med Sci. 1995 Feb-Mar;31(2-3):106-18 - PubMed
  55. Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96 - PubMed
  56. Thromb Haemost. 1997 Nov;78(5):1316-8 - PubMed
  57. J Thromb Haemost. 2004 Aug;2(8):1266-71 - PubMed
  58. Nat Med. 1996 Feb;2(2):209-15 - PubMed
  59. Ann Intern Med. 2001 Feb 6;134(3):191-202 - PubMed
  60. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7003-11 - PubMed
  61. J Clin Oncol. 2006 Jan 20;24(3):431-6 - PubMed
  62. J Cancer Res Clin Oncol. 1981;101(3):275-83 - PubMed
  63. JAMA. 2005 Feb 9;293(6):715-22 - PubMed
  64. Thromb Haemost. 1987 Oct 28;58(3):932-5 - PubMed
  65. Thromb Haemost. 1976 Jun 30;35(3):586-91 - PubMed
  66. Thromb Haemost. 2002 Apr;87(4):575-9 - PubMed
  67. Blood. 2006 Jul 1;108(1):403; author reply 404 - PubMed
  68. Circulation. 2004 Aug 17;110(7):874-9 - PubMed
  69. Thromb Haemost. 1994 Sep;72(3):330-4 - PubMed
  70. J Clin Oncol. 2005 Apr 1;23(10):2130-5 - PubMed
  71. Neoplasma. 2003;50(2):148-51 - PubMed
  72. Ann Intern Med. 2004 Jun 1;140(11):867-73 - PubMed
  73. N Engl J Med. 1992 Apr 9;326(15):975-82 - PubMed
  74. Br Med J. 1967 Oct 7;4(5570):25-6 - PubMed
  75. Am J Med. 1996 Mar;100(3):269-77 - PubMed
  76. J Clin Oncol. 2009 Oct 10;27(29):4902-11 - PubMed
  77. Clin Exp Metastasis. 1999 Jul;17(5):451-6 - PubMed
  78. Haemostasis. 1993 Mar;23 Suppl 1:141-9 - PubMed
  79. Invasion Metastasis. 1996;16(3):132-43 - PubMed
  80. Thromb Haemost. 1996 Feb;75(2):233-8 - PubMed
  81. J Neurosurg. 1973 Mar;38(3):337-8 - PubMed
  82. Cancer Res. 2000 Nov 1;60(21):6196-200 - PubMed
  83. N Engl J Med. 1988 Feb 18;318(7):404-7 - PubMed
  84. J Thromb Haemost. 2010 Sep;8(9):1959-65 - PubMed
  85. Arch Intern Med. 2002 Aug 12-26;162(15):1729-35 - PubMed
  86. Cancer Metastasis Rev. 1992 Nov;11(3-4):249-66 - PubMed
  87. J Clin Oncol. 2009 Oct 10;27(29):4895-901 - PubMed
  88. Am J Med. 2006 Jan;119(1):60-8 - PubMed
  89. Cancer Metastasis Rev. 1992 Nov;11(3-4):283-90 - PubMed
  90. Am J Med. 2006 Dec;119(12):1062-72 - PubMed
  91. N Engl J Med. 2003 Jul 10;349(2):146-53 - PubMed
  92. Thromb Haemost. 1997 Mar;77(3):456-61 - PubMed
  93. N Engl J Med. 2006 May 11;354(19):2079-80 - PubMed
  94. Haemostasis. 1997;27 Suppl 1:32-7 - PubMed
  95. JAMA. 1972 Aug 7;221(6):602-3 - PubMed
  96. Cancer Res. 2004 Apr 15;64(8):2743-50 - PubMed
  97. Circulation. 2005 Jul 19;112(3):416-22 - PubMed
  98. J Clin Oncol. 2004 May 15;22(10):1944-8 - PubMed
  99. Cancer Chemother Pharmacol. 2008 Jul;62(2):227-33 - PubMed
  100. Ann Intern Med. 1985 Jun;102(6):814-28 - PubMed
  101. Neurosurgery. 1998 Nov;43(5):1074-81 - PubMed
  102. J Clin Oncol. 2005 Apr 1;23(10):2123-9 - PubMed

Publication Types